Compare · MOVE vs SLNO
MOVE vs SLNO
Side-by-side comparison of Corvex Inc. (MOVE) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- MOVE operates in Technology, while SLNO operates in Health Care - the two are in different parts of the market.
- MOVE carries a market cap of $128.0M.
- MOVE has hit the wire 7 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 1 for MOVE).
- Company
- Corvex Inc.
- Soleno Therapeutics Inc.
- Price
- -
- -
- Market cap
- $128.0M
- -
- 1M return
- -58.04%
- -
- 1Y return
- -55.65%
- -
- Industry
- EDP Services
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2014
- News (4w)
- 7
- 0
- Recent ratings
- 1
- 12
Corvex Inc.
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest MOVE
- New insider Brian Dostie claimed ownership of 104,416 shares (SEC Form 3)
- Corvex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Corvex Signs $103 Million Take-or-Pay Agreement for NVIDIA Blackwell Capacity; $21 Million of Annual Contract Revenue per Megawatt
- SEC Form 10-Q filed by Corvex Inc.
- Corvex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Corvex Reports Third Quarter 2026 Results
- Corvex to Host Third Quarter 2026 Earnings Call on Thursday, November 12, 2026
- SEC Form 8-K filed by Corvex Inc.
- SEC Form 424B5 filed by Corvex Inc.
- SEC Form EFFECT filed by Corvex Inc.
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)